Emerging Technologies for HER2 Testing

Publisher： Karger

E-ISSN： 1423-0232|63|1|33-38

ISSN： 0030-2414

Source： Oncology, Vol.63, Iss.1, 2002-11, pp. : 33-38

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Testing for HER2 Status

By  

Oncology, Vol. 61, Iss. 2, 2001-10 ,pp. : 22-30

Karger

Access to resources Recommend Favorite

Current Status of HER2 Testing

By  

Oncology, Vol. 63, Iss. 1, 2002-11 ,pp. : 25-32

Karger

Access to resources Recommend Favorite

The FlexISH assay brings flexibility to cytogenetic HER2 testing

By  

HISTOPATHOLOGY, Vol. 69, Iss. 4, 2016-10 ,pp. : 635-646

John Wiley & Sons Inc

Access to resources Recommend Favorite

Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2‐negative breast cancer

By  

CANCER, Vol. 120, Iss. 17, 2014-09 ,pp. : 2657-2664

John Wiley & Sons Inc

Access to resources Recommend Favorite

Looking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analyses

By Ferrusi Ilia L   Marshall Deborah A   Kulin Nathalie A   Leighl Natasha B   Phillips Kathryn A  

Personalized Medicine, Vol. 6, Iss. 2, 2009-03 ,pp. : 193-215

Future Medicine

Access to resources Recommend Favorite